Overview
Dr. Arnold focuses on outcome research to demonstrate the cost-effectiveness of the therapies she uses. This includes incorporating patient reported outcomes, like quality of life, to survival and cost analysis. She hopes to demonstrate that novel therapies are effective and valuable because they enable children to grow up to become healthy, productive citizens in our society.
Her research incorporates local and national collaborations, which include the: Emory Pediatrics Qualitative Research Core, North American Pediatric Aplastic Anemia Consortium, and Sickle Cell Transplant Advocacy and Research Alliance.
- Erin Frost, MD, 2022-Present
Current Project: Role of Social Determinants of Health of Hematopoietic Cell Transplantation Referral
- Paul George, MD, 2021-Present
Current Project: Pollution and SCD Outcomes
- Thomas Michniacki, MD, Clinical lecturer, C.S. Mott Children's Hospital, 2018-Present
Current Project: Treatment-related Patient Reported Outcomes in Severe Pediatric Aplastic Anemia
- Lauren Johnson, MD, Morehouse School of Medicine, 2021-2024
- Bria Carrithers, MD (ASH Minority Medical Student Award Program Participant), Georgia Regents 2020
- Cameron Baldes, MD, Emory University, 2019-2020
- Jasmine Smith, MD (ASH Minority Medical Student Award Program Participant), University of South Carolina School of Medicine - Greenville, 2017
- Arnold SD, Bakshi N, Ross D, Abraham A, Bhatia M, Guilcher GMT, Smith C., Hsieh M, Kasow KA, Olowoselu FO, El-Rassi F, Haight A, Lane P, Meacham L, Stenger E, Krishnamurti L. Long term Quality of Life after Hematopoietic Cell Transplant for Sickle Cell Disease: a STELLAR Interim Analysis. AJH 2024.
- Basu A, Winn AN, Johnson KM, Jiao B, Devine B, Hankins JS, Arnold SD, Bender MA, Ramsey SD. Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States. Annals of Internal Medicine. 10.7326/M23-1520 [doi] PMID - 38252942
- Blue BJ, Brazauskas R, Chen K, Patel J, Zeidan AM, Steinberg A, Ballen K, Kwok J, Rotz SJ, Perez MAD, Kelkar AH, Ganguly S, Wingard JR, Lad D, Sharma A, Badawy SM, Lazarus HM, Hashem H, Szwajcer D, Knight JM, Bhatt NS, Page K, Beattie S, Arai Y, Liu H, Arnold SD, Freytes CO, Abid MB, Beitinjaneh A, Farhadfar N, Wirk B, Winestone LE, Agrawal V, Preussler JM, Seo S, Hashmi S, Lehmann L, Wood WA, Rangarajan HG, Saber W, Majhail NS. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis. Transplant Cell Ther. 2023 Nov;29(11):709.e1-709.e11. doi: 10.1016/j.jtct.2023.07.013. Epub 2023 Jul 22. PMID: 37482244
- Meacham LR, George S, Veludhandi A, Pruett MC, Haight AE, Arnold SD, Elchuri S, Stenger E, Krishnamurti L. Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: is Reduced Intensity better than Myeloablative Conditioning? Transplant Cell Ther. 2023 May 9:S2666-6367(23)01286-1. doi: 10.1016/j.jtct.2023.05.004. Epub ahead of print. PMID: 37169288.
- Stenger E, Xiang Y, Wetzel M, Gillespie S, Chellapandian D, Shah R, Arnold SD, Bhatia M, Chaudhury S, Eckrich MJ, Kanter J, Kasow KA, Krajewski J, Nickel RS, Ngwube AI, Olson TS, Rangarajan HG, Wobma H, Guilcher GMT, Horan JT, Krishnamurti L, Shenoy S, Abraham A. Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance. Transplant Cell Ther. 2023 Jan;29(1):47.e1-47.e10. doi: 10.1016/j.jtct.2022.10.012. Epub 2022 Oct 20. PMID: 36273784.
- Krishnamurti L, Arnold SD, Haight A, Abraham A, Guilcher GM, John T, Bakshi N, Shenoy S, Syrjala K, Martin PL, Chaudhury S, Eames G, Olowoselu OF, Hsieh M, De La Fuente J, Kasow KA, Stenger E, Mertens A, El-Rassi F, Lane P, Shaw BE, Meacham L, Archer D. Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study. JMIR Res Protoc. 2022 Jul 6;11(7):e36780. doi: 10.2196/36780. PMID: 35793124; PMCID: PMC9301564.
- Mupfudze TG, Meyer C, Preussler JM, Mau LW, Bolon YT, Steinert P, Arnold SD, Saber W, Krishnamurti L. Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease. Transplant Cell Ther. 2021 Aug;27(8):685.e1-685.e8. doi: 10.1016/j.jtct.2021.04.009. Epub 2021 Apr 22. PMID: 33895405; PMCID: PMC8680220.
- Bona K, Brazauskas R, He N, Lehmann L, Abdel-Azim H, Ahmed IA, Al-Homsi AS, Aljurf M, Arnold SD, Badawy SM, Battiwalla M, Beattie S, Bhatt NS, Dalal J, Dandoy CE, Diaz MA, Frangoul HA, Freytes CO, Ganguly S, George B, Gomez-Almaguer D, Hahn T, Kamble RT, Knight JM, LeMaistre CF, Law J, Lazarus HM, Majhail NS, Olsson RF, Preussler J, Savani BN, Schears R, Seo S, Sharma A, Srivastava A, Steinberg A, Szwajcer D, Wirk B, Yoshimi A, Khera N, Wood WA, Hashmi S, Duncan CN, Saber W. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood. 2021 Jan 28;137(4):556-568. doi: 10.1182/blood.2020006252. Erratum in: Blood. 2021 Dec 2;138(22):2300. PMID: 33104215; PMCID: PMC7845011.
- K23 2018-2024
- NIH-NHLBI 00103520 2022-2029
Co-Investigator PIs: Williams/Pulsipher/Shaw
- NIH-NIAID 1R24AI162637-01A1 2022-2027
Co-Investigator PI: Shimamura